NCT00088790已完成1 期
Phase I Study to Assess the Safety and Tolerability of AZD5438 in Patients With Advanced Solid Malignancies
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- AstraZeneca
- 试验地点
- 3
研究概览
简要总结
Purpose of this study is to assess the safety and tolerability of AZD5438 given orally to patients with advanced solid malignancies A review of the emerging clinical tolerability and exposure data from this study in conjunction with preclinical and the available clinical pharmacodynamic data relating to AZD5438, led to a decision by AstraZeneca that the development of AZD5438 as a potential anti-cancer agent would be discontinued.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Advanced solid malignancy
- •Cancer refractory to standard treatments or for which no standard therapy exits
排除标准
- •Radiotherapy within 3 weeks of the start of treatment
- •Investigational product within the last 3 weeks
- •Systemic cytotoxic anti-cancer therapy within the last 3 weeks
- •Any significant clinical disorder that makes it undesirable for the patient to participate
研究者
研究点 (3)
Loading locations...
相似试验
已完成
1 期
Study to Evaluate Safety, Tolerability and Pharmacokinetics (PK) (Including Food Effect) of Oral Doses of AZD5847 in Healthy VolunteersHealthyNCT01037725AstraZeneca64
已完成
1 期
A Study of Tor Kinase Inhibitor in Advanced TumorsSolid TumorsNCT00731263AstraZeneca64
已完成
1 期
Safety and Tolerability of AZD5148 in Japanese ParticipantsClostridioides Difficile InfectionNCT06639997AstraZeneca16
终止
1 期
Oral AZD8165 After Single Oral Ascending Doses in Healthy Male SubjectsThrombin InhibitionNCT01150812AstraZeneca9
撤回
1 期
AZD8075 Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Oral Doses of AZD8075 in Healthy Male VolunteersHealthyNCT00829127AstraZeneca27